The management of localized or locally advanced prostate cancer

American Journal of Cancer

Volumn 1, Issue 6, 2002, Pages 387-396

  Wirth, Manfred P ^a   Froehner, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; NILUTAMIDE;

ADJUVANT THERAPY; ADVANCED CANCER; BRACHYTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED RADIOTHERAPY; CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HORMONAL THERAPY; HUMAN; INTERSTITIAL RADIATION; MONOTHERAPY; PERIOPERATIVE PERIOD; POTENCY DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SURGICAL MORTALITY;

EID: 0042820283     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200201060-00002     Document Type: Review

References (82)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics. 2002. CA Cancer J Clin 2002; 52: 23-47
2. Schröder FH, Alexander FE, Bangma CH, et al. Screening and early detection of prostate cancer. Prostate 2000; 44: 255-63
3. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997; 80: 1835-44
4. Demers RY, Tiwari A, Wei J, et al. Trends in the utilisation of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer 2001; 92: 2309-17
5. Scardino PT. The Gordon Wilson Lecture: natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc 2000; 111: 201-41
6. American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology 2000; 14: 267-86
7. Schröder FH, Robol-Bouts M, Vis AN, et al. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology 2001; 57: 83-90
8. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer (2002). CA Cancer J Clin 2002; 52: 8-22
9. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-24
10. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound-guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-5
11. Davis M, Sofer M, Kim SS, et al. The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. J Urol 2002; 167: 566-70
12. Gore JL, Shariat SF, Miles BJ, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001; 165: 1554-9
13. Manseck A, Froehner M, Oehlschlaeger S, et al. Is systematic sextant biopsy suitable for the detection of clinically significant prostate cancer? Urol Int 2000; 65: 80-3
14. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-203
15. Steward CS, Leibovich BC, Weaver AL, et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsy. J Urol 2001; 166: 86-92
16. Manseck A, Fröhner M, Guhr K, et al. Ist die systematische Biopsie der Transitionalzone zusätzlich zur Sextantenbiopsie der Prostata sinnvoll? Akt Urol 2001; 32: 368-71
17. Deliveliotis C, Varkarakis J, Albanis S, et al. Biopsies of the transitional zone of the prostate: should it be done on a routine basis, when and why? Urol Int 2002; 68: 113-7
18. Sobin LH, Wittekind CH, editors. UICC: TNM classification of malignant tumours. 5th ed. New York: John Wiley & Sons, 1997
19. Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-8
20. Conrad S, Graefen M, Pichlmeier U, et al. Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol 2002; 167: 521-5
21. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA 1997; 277: 1445-51
22. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (partin tables) for the new millenium. Urology 2001; 58: 843-8
23. McNeal JE, Villers AA, Redwine EA, et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66: 1225-33
24. Ohori M, Wheeler TM, Scardino PT. The American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer: Clinicopathologic correlations. Cancer 1994; 74: 104-14
25. Freedland SJ, Csathy GS, Dorey F, et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002; 167: 516-20
26. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300
27. Granfors T, Modig H, Damber JE, et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998; 159: 2030-4
28. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
29. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavourable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG protocol 85-31. J Clin Oncol 1997; 15: 1013-21
30. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52
31. Scolieri MJ, Altman A, Resnick ML. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000; 164: 1465-72
32. Wirth MP, Froehner M. Perspectives in adjuvant treatment of prostate cancer. Urol Int 2002; 85: 1-5
33. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
34. Catalona WJ, Ramos GR, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999; 49: 282-96
35. Wirth M, Fröhner M. Diagnostik und individualisierte Therapie des lokoregionären Prostatakarzinoms. Urologe A 2000; 39: 578-87
36. Catalona WJ, Carvalhal GF, Mager DE, et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999; 162: 433-8
37. Davidson PJT, van den Ouden D, Schroeder FH. Radical prostatectomy: prospective assessment of mortality and morbidity. Eur Urol 1996; 29: 168-73
38. Middleton AW. Radical prostatectomy for carcinoma in men more than 69 years old. J Urol 1987; 138: 1185-8
39. Froehner M, Litz R, Manseck A, et al. Relationship of comorbidity, age and perioperative complications in patients undergoing radical prostatectomy. Urol Int 2001; 67: 283-8
40. Dillioglugil Ö, Leibman BD, Leibman NS, et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 1997; 157: 1760-7
41. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 91: 2302-14
42. Young HH. The early diagnosis and radical cure of carcinoma of the prostate: being a study of 40 cases and presentation of a radical operation which was carried out in 4 cases. Bull Johns Hopkins Hosp 1905; 16: 315-21
43. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982; 128: 492-7
44. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy, a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20: 286-92
45. Kupelian P, Katcher J, Levin H, et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249-60
46. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528-34
47. Lau WK, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002; 167: 117-22
48. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
49. Ornstein DK, Oh J, Herschman JD, et al. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 1998; 23: 591-601
50. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 1999; 17: 1155-62
51. Gerber GS, Thisted RA, Chodak GW, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997; 32: 385-90
52. Ghavamian R, Bergstralh EJ, Blute ML, et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999; 161: 1223-7
53. Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol 1996; 156: 450-3
54. Pollack A, Zagars GK. External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology 1998; 51: 258-64
55. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166: 876-81
56. Beard CJ, Lamb C, Cuswell L, et al. Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 257-62
57. Wirth MP, Hakenberg OW. Brachytherapy for prostate cancer. Urol Int 1999; 63: 87-91
58. Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998; 83: 989-1001
59. Ramos CG, Carvalhal GF, Smith DS, et al. Retrospective comparison of radical prostatectomy and 125Iodine brachytherapy for localized prostate cancer. J Urol 1999; 161: 1212-5
60. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20: 557-66
61. Beyer DC. The evolving role of prostate brachytherapy. Cancer Control 2001; 8: 163-70
62. Schmid HP, Semjonow A, Aus G, et al. Neoadjuvant hormonal therapy in radical prostatectomy and radiation-treated patients. Urol Int 2000; 65: 63-7
63. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997; 49 (3A Suppl.): 38-45
64. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-46
65. Pollack A, Zagars GK. Androgen ablation in addition to radiation therapy for prostate cancer: is there a true benefit? Semin Radiat Oncol 1998; 8: 95-106
66. Zincke H, Lau W, Bergstralh EJ, et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166: 2208-15
67. Wirth M, Frohmüller H, Marx F. Adjuvant antiandrogenic treatment after radical prostatectomy in stage C prostate cancer-preliminary results of a randomized controlled multicenter trial [abstract]. J Urol 1997; 157: 1308
68. Wirth M, Froehner M. A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol 1999; 36 Suppl. 2: 14-9
69. See WA, McLeod D, Iversen P, et al. The bicalutamide early prostate cancer program: demography. Urol Oncol 2001; 6: 43-7
70. Wirth M, Tyrrell C, Wallace M, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58: 146-51
71. Paulson DF, Moul JW, Robertson JE, et al. Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1990; 143: 1178-82
72. Valicenti RK, Gomella LG. Durable efficacy of adjuvant radiation therapy for prostate cancer: will the benefit last? Semin Urol Oncol 2000; 18: 115-20
73. Grossfeld GD, Tigrani VS, Nudell D, et al. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol 2000; 164: 93-9
74. Leibovich BC, Engen DE, Patterson DE, et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 2000; 163: 1178-82
75. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80
76. Drachenberg DE. Treatment of prostate cancer: watchful waiting, radical prostatectomy, and cryoablation. Semin Surg Oncol 2000; 18: 37-44
77. Ziethman AL, Thakral H, Wilson L, et al. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 2001; 166: 1702-6
78. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-82
79. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000; 88: 3009-14
80. Kolvenbag GJC, Iversen P, Newling DWW. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 2001; 58 Suppl. 2A: 16-23
81. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17: 2027-38
82. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56